Theravance Biopharma (TBPH) Stock: Buy, Sell, or Hold?
TBPH - Theravance Biopharma, Inc.
$17.01
-0.01 (-0.06%)
âŧ
5d:
-0.41%
30d:
+0.53%
90d:
+3.15%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When TBPH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: TBPH is fairly priced but lacks strong directional signals. At 0.5% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: TBPH is fairly priced but lacks strong directional signals. At 0.5% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$32.77
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$20.35
16.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TBPH is currently trading at $17.01, which is considered fair relative to its 30-day fair value range of $16.93 to $17.05. The stock's valuation (Forward PE: 13.3) is in line with its historical norms (13.2). At these levels, the market is pricing in 0.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TBPH is in a uptrend. The price is currently testing key support at $17.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TBPH is in a uptrend. The price is currently testing key support at $17.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$16.93 -
$17.05
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($17.67)
- NEUTRAL: Market pricing in 0.5% annual earnings growth - fairly valued
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$16.93 -
$17.05
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$17.00
Resistance Level
$17.26
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.34
Wall Street Target
$17.67
(+3.9%)
Revenue Growth (YoY)
-20.9%
Profit Margin
51.6%
Valuation Premium vs History
+0.5% premium
PE vs Historical
13.3 vs 13.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.5%
(market-implied from PE analysis)
1-Year Target
$17.10
(+1%)
2-Year Target
$17.18
(+1%)
3-Year Target
$17.27
(+2%)
3-Yr Target (if PE normalizes)
(PE: 13â13)
PE COMPRESSION
$17.08
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 507.1%)
$86.79
(+410%)
Base:
(SPY PE: 13.3, Growth: 507.1%)
$57.41
(+238%)
Bear:
(PE: 11.3, Growth: 507.1%)
$48.80
(+187%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 16.37 | Current EPS (TTM): $1.04
Bull Case
$22.95
(+35%)
Analyst growth 22.6%, PE expands to 18.0
Base Case
$20.87
(+23%)
Market implied 22.6%, PE stable at 16.4
Bear Case
$11.57
(-32%)
Severe decline -20.0%, PE contracts to 13.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 13, 2026 7:48 AM ET
Data refreshes hourly during market hours. Next update: 8:48 AM
Data refreshes hourly during market hours. Next update: 8:48 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TBPH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
